Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Jan 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-01-01

Reporting Person: Greenleaf Peter (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8328	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$6.28	2029-04-29	Common Stock (1600000)		Direct
Stock Option (right to buy)	$19.41	2030-02-05	Common Stock (412776)		Direct
Stock Option (right to buy)	$13.03	2030-12-21	Common Stock (817024)		Direct

Footnotes

F1: One-fourth of the shares subject to the option vests twelve months from the grant date, and the remainder vests in thirty-six equal monthly installments thereafter.

F2: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F3: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.